Ann: Race starts preclinical breast cancer study for Bisantrene, page-56

There can be a little more added to this that @IndexInvestor should really have generously explained to you.

Zantrene was shown to be significantly more potent (between 2x and 5x) than other anthracyclines in MCF-7 breast cancer cells resistant to a number of different SoC drugs.



The MCF-7 cells used in this trial have been previously identified as breast cancer cells that have upregulated FTO (1,2).

MCF-7 cells that had been pre-treated with Doxorubicin lead to an upregulation of FTO (3). I speculate that pretreatment of the SoC drugs in the MCF-7 breast cancer cells may have upregulated cellular FTO, which is why Bisantrene was sensitive and the other anthracyclines were not (the upregulated FTO led to drug resistance).

Based on this data, I am very confident that the results observed in the most recently announced preclinical breast cancer results is a result of Zantrene inhibtiing FTO in these cell lines. An interesting thought provoker is the magnitude or scale of FTO upregulation being central to anti-cancer therapy resistance.

The preclinical breast cancer program is continuing, which I believe will include mouse models and drug combinations with a multi-billion dollar breast cancer drug like a HER-2 monoclonal (I think likely), or maybe even something like Trodelvy. There might be other possible and more likely drug combinations, but it's a bit late for me in Perth and that's all I can come up with.

1 https://www.spandidos-publications.com/10.3892/ol.2017.6038
2 https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-1004-4
3 https://www.tandfonline.com/doi/full/10.1080/21655979.2021.1924544